JAMIE BURTON, MD

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

New patient office or other outpatient visit, 60-74 minutes

Administration of chemotherapy into vein, 1 hour or less

New patient office or other outpatient visit, 45-59 minutes

Established patient office or other outpatient visit, 40-54 minutes

Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

Sarscv2 vac 30mcg trs-suc im

Administration of chemotherapy into vein using push technique

Established patient office or other outpatient visit, 30-39 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Injection, zoledronic acid, 1 mg

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Injection, fulvestrant, 25 mg

Administration of additional new drug or substance into vein, 1 hour or less

Administration of additional new drug or substance into vein using push technique

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Established patient office or other outpatient visit, 20-29 minutes

Flow cytometry technique for dna or cell analysis, first marker

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Injection, carboplatin, 50 mg

Admn sarscov2 vacc 1 dose

Injection of drug or substance into vein

Infusion into a vein for hydration, 31-60 minutes

Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

Injection, pembrolizumab, 1 mg

Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Administration of chemotherapy into vein, each additional hour

Flow cytometry technique for dna or cell analysis, each additional marker

Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free

Immunologic analysis technique on serum (immunofixation)

Injection, leucovorin calcium, per 50 mg

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Application of on-body injector for under skin injection

Injection, nivolumab, 1 mg

Vitamin d-3 level

Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3

Immunologic analysis for detection of tumor antigen, quantitative; ca 125

Injection of drug or substance under skin or into muscle

Injection, palonosetron hcl, 25 mcg

Injection of additional new drug or substance into vein

Carcinoembryonic antigen (cea) protein level

Protein measurement, serum

Injection, epoetin alfa, (for non-esrd use), 1000 units

Alpha-fetoprotein (afp) level, serum

Cortisol (hormone) measurement, total

Injection, ferric derisomaltose, 10 mg

Blood test, thyroid stimulating hormone (tsh)